Breast Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBreast CancerBreast CancerSCE Medical Oncology

A 48-year-old woman with metastatic TNBC and PD-L1 CPS 12 is starting first-line therapy. She has not received prior immunotherapy. What is the standard first-line regimen?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Pembrolizumab + nab-paclitaxel or paclitaxel

The KEYNOTE-355 trial demonstrated that pembrolizumab + chemotherapy (nab-paclitaxel, paclitaxel or gemcitabine-carboplatin) significantly improved PFS and OS compared with chemotherapy alone in metastatic TNBC with PD-L1 CPS ≥10 (NICE TA801). Atezolizumab + nab-paclitaxel (IMpassion130) was previously used but atezolizumab was voluntarily withdrawn from this indication following IMpassion131 failure.

Reference: NICE TA801 Pembrolizumab with chemotherapy for untreated PD-L1-positive TNBC; KEYNOTE-355